$1.390
-0.029 (-2.11%)Al cierre
- High
- 1.440
- Open
- 1.440
- VWAP
- 1.40
- Vol
- 73.72K
- Mkt Cap
- —
- Low
- 1.380
- Amount
- 103.45K
- EV/EBITDA, TTM
- -2.40
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
AI analysis of MindWalk Holdings Corp (HYFT)
buyMindWalk Holdings Corp (HYFT) is a good buy right now due to its recent inclusion in the Russell 3000 Index, which is expected to enhance visibility and attract institutional investors. The stock has shown a 52% year-over-year revenue growth in Q3, reaching $4.2 million, and a gross margin improvement to 60.63% in Q4 2026. However, the main risk is the negative earnings per share (EPS) of -0.08, indicating ongoing losses, but the potential for recovery is strong given the positive market sentiment and analyst support.
Métricas de valoración
Cronología de eventos
Noticias
8.508-19NewsfilterAI Drug Discovery Enters New Phase with Big Pharma Validation
- 8.508-10Newsfilter
MindWalk Holdings Demonstrates AI Drug Discovery Technology
8.507-24PRnewswireMindWalk Unveils AI Drug Discovery Platform at AMD Event
- 3.507-24Newsfilter
MindWalk Unveils AI Drug Discovery Platform at AMD Event
9.507-23PRnewswireMindWalk Holdings Reports 46% Revenue Growth in Fiscal 2026
HYFT FAQ — answered by Alphio AI
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. It operates in the Healthcare sector.
MindWalk Holdings Corp (HYFT) is a good buy right now due to its recent inclusion in the Russell 3000 Index, which is expected to enhance visibility and attract institutional investors. The stock has shown a 52% year-over-year revenue growth in Q3, reaching $4.2 million, and a gross margin improvement to 60.63% in Q4 2026. However, the main risk is the negative earnings per share (EPS) of -0.08, indicating ongoing losses, but the potential for recovery is strong given the positive market sentiment and analyst support.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.